A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 3, 2007, Pages 313-320

  Jeung, Hei Cheul ^a   Rha, Sun Young ^a,b   Noh, Sung Hoon ^b   Roh, Jae Kyung ^a,b   Chung, Hyun Cheol ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Cisplatin; Gastric neoplasms; Irinotecan; Phase II; Weekly fractionation

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 33845887710     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0272-z     Document Type: Article

References (26)

1. Ajani JA, Baker J, Pisters PWT, Ho L, Mansfield PF, Feig BW, Charnsangavej C (2002) Irinotecan plus cisplatin in patients with advanced untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94:641
2. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319
3. Cascinu S, Graziano F, Barni S, Labianca R, Comella G, Casaretti R, Frontini L, Catalano V, Baldelli AM, Catalano G (2001) A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 84:470
4. Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi V, Luppi G, Mazzocchi B, Rodino C, Soldani M (1994) Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12:2687
5. Dickson JLB, Cunningham D (1997) Systemic treatment of gastric cancer. Eur J Gastroentrol Hepatol 16:255
6. Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P, Cognetti F (2003) Docetaxel in advanced gastric cancer: review of the main clinical trials. Acta Oncol 42:693
7. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163
8. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzales G, Kelsen DP (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270
9. Kambe M, Wakui A, Nakano I (1993) A late phase II study of irinotecan in patients with advanced gastric cancers. Proc Am Soc Clin Oncol 12:198 (abstr 584)
10. Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T (1995) Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 86:406
11. Lee JA, Yoon SS, Yang SH, Kim SY, Heo DS, Bang YJ, Cho KS, Kim NK (1993) FAM versus etoposide, adriamycin, and cisplatin: a random assignment trial in advanced gastric cancer. J Kor Cancer Ass 25:461
12. Masumoto N, Nakano S, Esaki T, Fujishima H, Tatsumoto T, Niho Y (1995) Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous carcinoma cells. Int J Cancer 62:70
13. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72:37
14. Nakamura T, Nakajima Y, Enomoto T, Hori S, Hidaka T, Murata Y, Saito S (2004) Cisplatin enhances the p53-independent apoptosis induced y a tomoisomerase I inhibitor (CPT-11) in the lens epithelial tumors in transgenic mice. Oncol Rep 12:253
15. Pisters PWT, Kelsen DP, Powell SM, Tepper JE (2005) Cancer of the stomach. In: DeVita VT (ed) Cancer: principle and practice in oncology. Lippincott Williams and Wilkins, Philadelphia, pp 909-944
16. Pozzo C, Bugat R, Peschel C, Gorbunova V, Valvere V, Zaluski J, Biakhov M (2001) Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastroesophageal junction adenocarcinoma: final results of a randomized phase II study. Proc Am Soc Clin Oncol 20:134 (abstr 531)
17. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R (2004) Irinotecan in combination with 5-fluorouracil and folinic acid in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15:1773
18. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301
19. Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D (1998) Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol 16:3858
20. Shimoyama S, Aoki F, Shimizu N, Tatsutomi Y, Mafune K, Kaminishi M (2003) Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (IRINOTECAN) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report. Int J Clin Oncol 8:49
21. Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S (1997) Phase I-II study of irinotecan hydrochloride combined with cisplatin against metastatic gastric cancer. J Clin Oncol 15:921
22. Simon R (1989) Optimal two-stage design for phase II clinical trials. Control Clin Trials 10:1
23. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Pledbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648
24. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80:269
25. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261
26. Yamao T, Kai S, Kazani A, Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, Maruyama M (1999) Tumor markers CEA, CA19-9, and CA125 in monitoring response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol 29:550